AstraZeneca Pharmaceuticals LP has recalled 807,837 units of the 120-inhalation canister and 235,698 units of the 28-inhalation canister of Airsupra (albuterol and budesonide) inhalation aerosol. The recall is due to a defective delivery system that may prevent the inhaler from dispensing the medication correctly. This product is a prescription medication used to treat or prevent symptoms of asthma.
A defective delivery system can prevent a patient from receiving their required dose of medication during an asthma attack or for routine symptom management. This failure could lead to worsening respiratory symptoms or a medical emergency if the rescue medication is unavailable when needed.
You have 2 options:
Units affected: 807,837 canisters
Units affected: 235,698 canisters
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.